A Vast Unmet Need

Market Opportunity

Despite billions spent on research, there is still no cure for Alzheimer’s Disease (AD).

Since 1995, $42.5B has been invested in more than 1,000 trials.

Meeting the Demand

The Market is Everyone

To quantify the waiting market for a physician-prescribed, FDA-approved therapeutic that is reimbursed through insurance is straightforward. It’s everyone who has the disease.

An estimated 6.5 million Americans age 65 and older were living with Alzheimer’s dementia in 2022, about 1 in 9 people (10.7%).

And demand is growing at a staggering rate.

Global Data estimates by 2026, 23.8M Americans over the age of 60 will have MCI, Mild AD, Moderate AD or Severe AD.
The percentage of people with Alzheimer’s dementia increases with age: 5.0% of people aged 65 to 74, 13.1% of people aged 75 to 84, and 33.2% of people aged 85 and older have Alzheimer’s dementia

The population of Americans 65 and older is projected to grow from 58 million in 2021 to 88 million by 2050.

The dollar value of the market is large and growing.

The US market, which was valued at $720M in 2021, is estimated to be worth $11.3B by 2030. The global market is estimated to be worth $15.6B by 2030.

A Digital Revolution in Medicine

The Digital Therapeutics Market

Prescription Digital Therapeutics (PTDs), a relatively new class of medicine recognized by the FDA, are gaining wide acceptance across the medical spectrum. Irritable bowel syndrome, eczema, respiratory disease and diabetes are just a few of the indications doctors are treating with tech.

By 2029, the PTD market is projected to be valued at $26.3B.

It’s easy to see why this market is booming. Most PTDs—like ours—offer the convenience of in-home use. Many are delivered via technology that patients already own—e.g., mobile phones or tablets. Treatment can be highly individualized, and data capture allows doctors to quickly know how well it’s working. Some even include a game-like experience, which is great for patient compliance.

The Economic Impact of Alzheimer’s

Since 2000, deaths from Alzheimer’s disease have increased by 89%.

In the United States, without a means of prevention or a cure, this disease will contribute cumulative costs of almost $20 trillion to Medicare and Medicaid spending by 2050.

In 2022, the total national cost of caring for people living with Alzheimer’s and other dementias was estimated at $321 billion.

In 2021, unpaid dementia caregiving was estimated to be 16 billion hours, valued at $271.6 billion.

News & Publications

Read All News